Trials / Recruiting
RecruitingNCT05510323
Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD
Efficacy and Safety of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 Chronic Kidney Disease
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 208 (estimated)
- Sponsor
- Air Force Military Medical University, China · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical trial is to evaluate the long-term efficacy and safety of low-dose oral corticosteroids combined with cyclophosphamide therapy and low-dose corticosteroids monotherapy, on a background of maximal RAS inhibitor therapy, for IgA nephropathy with stage 3 or 4 chronic kidney disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prednisolone | RAS blockade as much as tolerated or allowed |
| DRUG | Prednisolone plus Cyclophosphamide | RAS blockade as much as tolerated or allowed |
Timeline
- Start date
- 2024-02-01
- Primary completion
- 2025-08-01
- Completion
- 2028-08-01
- First posted
- 2022-08-22
- Last updated
- 2024-05-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05510323. Inclusion in this directory is not an endorsement.